Skip to main content
NCBI home page
British Medical Journal (Clinical Research Ed.) logoLink to British Medical Journal (Clinical Research Ed.)
. 1984 Feb 18;288(6416):515–518. doi: 10.1136/bmj.288.6416.515

Development of pituitary adenoma in women with hyperprolactinaemia: clinical, endocrine, and radiological characteristics.

A E Pontiroli, L Falsetti
PMCID: PMC1444557  PMID: 6421360

Abstract

Sixty eight women referred for treatment of hyperprolactinaemia entered a three year follow up study to determine the clinical and endocrine course of the disease and its association with microadenoma of the pituitary. Details recorded before treatment included medical history, gonadotrophin and ovarian hormonal concentrations, and release of prolactin in response to protirelin (thyrotrophin releasing hormone), benserazide, cimetidine, and nomifensine. Sellar tomography was then performed yearly for three years in all women, 54 of them also undergoing computed coronal and sagittal tomography. At baseline evaluation 27 women showed radiological evidence of pituitary adenoma; at the end of the follow up period the number had increased to 41. Amenorrhoea, steady and raised serum prolactin concentrations, a low ratio of luteinising hormone to follicle stimulating hormone, a longer duration of disease, and low serum progesterone concentrations were more common in women with a final diagnosis of pituitary adenoma than in those whose sella remained normal. Tests for release of prolactin had yielded abnormal results from the outset in all 41 women with radiological evidence of pituitary adenoma and in about half of those whose sella had remained radiologically normal. Response to medical treatment (metergoline in 20 patients, bromocriptine in 21) was similar and showed no difference between patients with tumorous and non-tumorous hyperprolactinaemia. These findings suggest that a large proportion of women with hyperprolactinaemia may harbour a prolactin secreting pituitary adenoma which becomes apparent over a relatively short period. Amenorrhoea and steady and raised serum prolactin concentrations are more common in these women. Tests for release of prolactin are of predictive value in identifying women who will develop a pituitary adenoma.

Full text

PDF
515

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Burrow G. N., Wortzman G., Rewcastle N. B., Holgate R. C., Kovacs K. Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series. N Engl J Med. 1981 Jan 15;304(3):156–158. doi: 10.1056/NEJM198101153040306. [DOI] [PubMed] [Google Scholar]
  2. Fine S. A., Frohman L. A. Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors. J Clin Invest. 1978 Apr;61(4):973–980. doi: 10.1172/JCI109022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Gonzalez-Villapando C., Szabo M., Frohman L. A. Central nervous system-mediated stimulation of prolactin secretion by cimetidine, a histamine H2-receptor antagonist: impaired responsiveness in patients with prolactin-secreting tumors and idiopathic hyperprolactinemia. J Clin Endocrinol Metab. 1980 Dec;51(6):1417–1424. doi: 10.1210/jcem-51-6-1417. [DOI] [PubMed] [Google Scholar]
  4. Gómez F., Reyes F. I., Faiman C. Nonpuerperal galactorrhea and hyperprolactinemia. Clinical findings, endocrine features and therapeutic responses in 56 cases. Am J Med. 1977 May;62(5):648–660. doi: 10.1016/0002-9343(77)90866-x. [DOI] [PubMed] [Google Scholar]
  5. Hyperprolactinaemia: pituitary tumour or not? Lancet. 1980 Mar 8;1(8167):517–519. [PubMed] [Google Scholar]
  6. Hökfelt T., Fuxe K. Effects of prolactin and ergot alkaloids on the tubero-infundibular dopamine (DA) neurons. Neuroendocrinology. 1972;9(2):100–122. doi: 10.1159/000122042. [DOI] [PubMed] [Google Scholar]
  7. Jeske W. The effect of metoclopramide, TRH and L-dopa on prolactin secretion in pituitary adenoma and in "functional" galactorrhoea syndrome. Acta Endocrinol (Copenh) 1979 Jul;91(3):385–396. doi: 10.1530/acta.0.0910385. [DOI] [PubMed] [Google Scholar]
  8. Keye W. R., Jr, Chang R. J., Jaffe R. B. Hyperprolactinemic amenorrhea. N Engl J Med. 1977 Aug 18;297(7):396–397. doi: 10.1056/NEJM197708182970716. [DOI] [PubMed] [Google Scholar]
  9. MacGregor C., Maldonado D., Canales E. S., Soria J., Zárate A. Prolactin responsiveness to TRH in amenorrheic women with and without galactorrhea. Acta Obstet Gynecol Scand. 1977;56(4):333–336. doi: 10.3109/00016347709154988. [DOI] [PubMed] [Google Scholar]
  10. Müller E. E., Genazzani A. R., Murru S. Nomifensine: diagnostic test in hyperprolactinemic states. J Clin Endocrinol Metab. 1978 Dec;47(6):1352–1357. doi: 10.1210/jcem-47-6-1352. [DOI] [PubMed] [Google Scholar]
  11. Pontiroli A. E., Alberetto M., Pellicciotta G., De Castro e Silva E., De Pasqua A., Girardi A. M., Pozza G. Interaction of dopaminergic and antiserotoninergic drugs in the control of prolactin and LH release in normal women. Acta Endocrinol (Copenh) 1980 Mar;93(3):271–276. doi: 10.1530/acta.0.0930271. [DOI] [PubMed] [Google Scholar]
  12. Pontiroli A. E., De Castro e Silva E., Mazzoleni F., Alberetto M., Baio G., Pellicciotta G., De Pasqua A., Stella L., Girardi A. M., Pozza G. The effect of histamine and H1 and H2 receptors on prolactin and luteinizing hormone release in humans: sex differences and the role of stress. J Clin Endocrinol Metab. 1981 May;52(5):924–928. doi: 10.1210/jcem-52-5-924. [DOI] [PubMed] [Google Scholar]
  13. Pontiroli A. E., Falsetti L., Voltolini A. M., Alberetto M., Pellicciotta G., de Pasqua A., Girardi A. M., Pozza G. Benserazide, a stimulator of prolactin release: a new test in the diagnosis of pituitary prolactin-secreting tumours. Acta Endocrinol (Copenh) 1981 Nov;98(3):326–332. doi: 10.1530/acta.0.0980326. [DOI] [PubMed] [Google Scholar]
  14. Pontiroli A. E., Loda G., Roggia A., Scagliola P., Falsetti L. Benserazide and nomifensine in the diagnosis of prolactin-secreting pituitary adenomas. Acta Endocrinol (Copenh) 1982 Oct;101(2):171–179. doi: 10.1530/acta.0.1010171. [DOI] [PubMed] [Google Scholar]
  15. Rjosk H. K., Fahlbusch R., von Werder K. Spontaneous development of hyperprolactinaemia. Acta Endocrinol (Copenh) 1982 Jul;100(3):333–336. doi: 10.1530/acta.0.1000333. [DOI] [PubMed] [Google Scholar]
  16. Serri O., Rasio E., Beauregard H., Hardy J., Somma M. Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. N Engl J Med. 1983 Aug 4;309(5):280–283. doi: 10.1056/NEJM198308043090505. [DOI] [PubMed] [Google Scholar]
  17. Swanson H. A., Du Boulay G. Borderline variants of the normal pituitary fossa. Br J Radiol. 1975 May;48(569):366–369. doi: 10.1259/0007-1285-48-569-366. [DOI] [PubMed] [Google Scholar]
  18. Tucker H. S., Grubb S. R., Wigand J. P., Taylon A., Lankford H. V., Blackard W. G., Becker D. P. Galactorrhea-amenorrhea syndrome: follow-up of forty-five patients after pituitary tumor removal. Ann Intern Med. 1981 Mar;94(3):302–307. doi: 10.7326/0003-4819-94-3-302. [DOI] [PubMed] [Google Scholar]
  19. Vezina J. L., Sutton T. J. Prolactin-secreting pituitary microadenomas: roentgenologic diagnosis. Am J Roentgenol Radium Ther Nucl Med. 1974 Jan;120(1):46–54. doi: 10.2214/ajr.120.1.46. [DOI] [PubMed] [Google Scholar]
  20. Wiebe R. H., Hammond C. B., Borchert L. G. Diagnosis of prolactin-secreting pituitary microadenoma. Am J Obstet Gynecol. 1976 Dec 15;126(8):993–996. doi: 10.1016/0002-9378(76)90690-6. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal (Clinical research ed.) are provided here courtesy of BMJ Publishing Group

RESOURCES